Rankings
▼
Calendar
CTMX FY 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$138M
+36.4% YoY
Gross Profit
$138M
100.0% margin
Operating Income
$25M
18.1% margin
Net Income
$32M
23.1% margin
EPS (Diluted)
$0.38
Cash Flow
Operating Cash Flow
-$86M
Free Cash Flow
-$87M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$121M
Total Liabilities
$121M
Stockholders' Equity
-$456,000
Cash & Equivalents
$38M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$138M
$101M
+36.4%
Gross Profit
$138M
$101M
+36.4%
Operating Income
$25M
-$6M
+485.5%
Net Income
$32M
-$569,000
+5700.9%
← Q4 2023
All Quarters
Q1 2024 →